Going
BEYOND THE 21ST CENTURY
Covering Controversial Topics & Essential Skills of The Future
Scroll Down
Programme
DAY 2 PANEL DISCUSSION
CELL & GENE THERAPY
The panel discussion will explore the innovative advances in technologies pertaining to cell and gene therapies that can potentially serve as cures to conditions that are once thought impossible to treat. Its limitations, ethics, and prospect in actualising this form of treatment to the world will also be examined. With these in mind, to what extent should such therapies be integrated into the prevailing medical treatments?
OUR PANEL
(From left to right)
Prof Kon Oi Lian (Deputy Chair of BAC);
Mr. Hugh Mckee (Senior Process Consultant of PM Group);
Sankaran Rajan (General Manager of GE Healthcare);
Dr Chionh Yok Hian (Principal Scientist of Tychan Pte Ltd);
Dr Aparna Venkatesh (Senior Research Fellow of A*Star Singapore)
HEALTHCARE DATA SERIES
KEYNOTE SHARINGS
With more and more medical records being converted to EMR (electronic medical records), digital data is now the new oil which fuels the healthcare industry. With the recent data breach incidents, what can we do to ensure that these data are well protected and secured? Find out more here!
Session 1:
Digital Management of Healthcare Data
As we step into the fourth industrial revolution, more and more of our healthcare data is being digitalised. How should we manage such huge volume of data? Hear from the experts!
Session 2:
Healthcare Data
Breach
The recent healthcare data breach took the nation by shock. What exactly happened and what are the measure that we can take to ensure that our data is safe and secured? Hear from the experts themselves!
Session 1 & 2 : PANELIST
OUR
PANEL
Lam Shao Wei Sean, Senior Data Science Manager, SingHealth Health Services Research Centre
Dario Heymann, Chief Research Officer, Galen Growth Asia
SERIES
OPERATIONAL EXCELLENCE
Operational excellence is key in ensuring efficiency in production and manufacturing of drugs. How are operations in the pharmaceutical industry simplified and enhanced? Find out more here!
Session 1:
Operational Excellence - How to change things when change is harD
Wilbur Ho, Director of Operations, Amgen Singapore
​
Explore ways to launch, champion projects in highly matrix organisations typical of biopharmaceutical technical operations. Mr. Ho will share his experience driving for results when seemingly no one is willing to change and how soft skills are vital to any Operational Excellence project execution.
Session 2:
Achieving operational excellence
Christian Cater, Head of Operational Excellence, Roche
​
Operational Excellence and change go hand in hand. Whether on a technology platform or a cultural platform, changing how people work, think, and behave is the key to optimize a business operation. In the pharmaceutical industry, the time and resources used to develop, and groom talent takes different leadership skills. Gone is the day of the top down manager who directs others. In today's VUCA world, a leader requires agility, flexibility and the patience to give away control. Hear what it takes to be a leader in this industry.
SERIES
NOVEL TECHNOLOGIES
With the turn of the century, novel technologies have enabled many new drug discoveries while looking to change the way we view healthcare. What are effects of these novel technologies and how do they affect patient care? Find out more here!
Session 1:
MAXIMISING patient access TO INNOVATIVE MEDICINES
Candice Wong, Brand Manager of AstraZeneca
​
Innovative medicines have greatly improved the lives of people globally. Research and development of new, innovative drugs come with high costs. This presentation aims to address the strategies to ensure that most patients can benefit from innovative medicines while maintaining a sustainable healthcare system and continuous research and development.
Session 2:
Genotyping Patients to optimise Drug Choices: Applicability and Concern
Dr. Astrid Irwanto, GIS Innovation Fellow
​
​Pharmacogenomics is the study of how genes affect a person’s response to drugs. It has high potential to reduce adverse reactions, as 30% of such events are related to genetic factors. Our local Singapore data has also shown that reducing an adverse reaction could potentially save SGD7,150 per patient. I will discuss the importance of looking into multiple aspects, the challenges and how we can try to overcome them to ensure clinical implementation of pharmacogenomics eventually can translate to tangible benefits to patients and society, especially in Asia.
SERIES
PROJECT MANAGEMENT
Having project management skills are key in the 21st Century. How are there project management skills practiced in the pharmaceutical industry? Find out more here!
Session 1:
Fundamentals of Project Management
(Time, Cost & Scope)
Geoffery Brow, QA/QC Manager at Exyte Singapore
An introduction to the fundamental components pertaining to project management i.e. time, cost & scope & how they can be optimised
Session 2:
ADVANCE Project Management - MANAGING RELATIONSHIPS
Liu Shan Shan, Senior Manager, No Deviation Pte Ltd
Speaker would like the topic to remain confidential